[1]
|
中国抗癌协会淋巴瘤专业委员会, 中国医师协会肿瘤医师分会, 中国医疗保健国际交流促进会肿瘤内科分会. 中国淋巴瘤治疗指南(2021年版) [J]. 中华肿瘤杂志, 2021, 43(7): 707-735.
https://doi.org/10.3760/cma.j.cn112152-20210516-00382
|
[2]
|
Goldfinger, M. and Cooper, D.L. (2021) Lenalido-mide in DLBCL: Are We Past the Cell of Origin? Clinical Advances in Hematology & Oncology, 19, 320-325.
|
[3]
|
肖远喆, 张清媛. 弥漫性大B细胞淋巴瘤免疫治疗进展[J]. 现代肿瘤学, 2022, 30(18): 3441-3444.
|
[4]
|
Arneth, B. (2019) Tumor Microenvironment. Medicina, 56, Article 15. https://doi.org/10.3390/medicina56010015
|
[5]
|
Spill, F., Reynolds, D.S., Kamm, R.D. and Zaman, M.H. (2016) Impact of the Physical Microenvironment on Tumor Progres-sion and Metastasis. Current Opinion in Biotechnology, 40, 41-48.
https://doi.org/10.1016/j.copbio.2016.02.007
|
[6]
|
Del Prete, A., Schioppa, T., Tiberio, L., et al. (2017) Leukocyte Trafficking in Tumor Microenvironment. Current Opinion in Pharmacology, 35, 40-47. https://doi.org/10.1016/j.coph.2017.05.004
|
[7]
|
Dunn, G.P., Old, L.J. and Schreiber, R.D. (2004) The Three Es of Cancer Immunoediting. Annual Review of Immunology, 22, 329-360. https://doi.org/10.1146/annurev.immunol.22.012703.104803
|
[8]
|
Cycon, K.A., Rimsza, L.M. and Murphy, S.P. (2009) Alterations in CIITA Constitute a Common Mechanism Accounting for Downregulation of MHC Class II Ex-pression in Diffuse Large B-Cell Lymphoma (DLBCL). Experimental Hematology, 37, 184-194. https://doi.org/10.1016/j.exphem.2008.10.001
|
[9]
|
Wada, N., Zaki, M.A., Hori, Y., Hashimoto, K., Tsukaguchi, M., Tatsumi, Y., Ishikawa, J., Tominaga, N., Sakoda, H., Take, H., Tsudo, M., Kuwayama, M., Morii, E., Aozasa, K. and Osaka Lymphoma Study Group (2012) Tumour-Associated Macrophages in Diffuse Large B-Cell Lymphoma: A Study of the Osaka Lymphoma Study Group. Histopathology, 60, 313-319. https://doi.org/10.1111/j.1365-2559.2011.04096.x
|
[10]
|
Lau, S.K., Chu, P.G. and Weiss, L.M. (2004) CD163: A Specific Marker of Macrophages in Paraffin-Embedded Tissue Samples. American Journal of Clinical Pathology, 122, 794-801. https://doi.org/10.1309/QHD6-YFN8-1KQX-UUH6
|
[11]
|
Riihijärvi, S., Fiskvik, I., Taskinen, M., Vaja-vaara, H., Tikkala, M., Yri, O., Karjalainen-Lindsberg, M.L., Delabie, J., Smeland, E., Holte, H. and Leppä, S. (2015) Prognostic Influence of Macrophages in Patients with Diffuse Large B-Cell Lymphoma: A Correlative Study from a Nordic Phase II Trial. Haematologica, 100, 238-245.
https://doi.org/10.3324/haematol.2014.113472
|
[12]
|
Nam, S.J., Go, H., Paik, J.H., Kim, T.M., Heo, D.S., Kim, C.W. and Jeon, Y.K. (2014) An Increase of M2 Macrophages Predicts Poor Prognosis in Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone. Leukemia & Lymphoma, 55, 2466-2476.
https://doi.org/10.3109/10428194.2013.879713
|
[13]
|
罗燕珍, 周达, 陈思静, 廖成成, 王明月, 谭晓虹, 柯晴, 岑洪. 肿瘤相关巨噬细胞与弥漫大B细胞淋巴瘤预后的关系[J]. 中国癌症防治杂志, 2022, 14(1): 87-93.
|
[14]
|
Ruffell, B., Affara, N.I. and Coussens, L.M. (2012) Differential Macrophage Programming in the Tumor Microenvironment. Trends in Immunology, 33, 119-126. https://doi.org/10.1016/j.it.2011.12.001
|
[15]
|
Matsuki, E., Bohn, O.L., El Jamal, S., Pichardo, J.D., Zelenetz, A.D., Younes, A. and Teruya-Feldstein, J. (2019) Lympho-cyte-to-Monocyte Ratio May Serve as a Better Prognostic Indicator than Tumor-associated Macrophages in DLBCL Treated with Rituximab. Applied Immunohistochemistry & Molecular Morphology, 27, 572-580.
https://doi.org/10.1097/PAI.0000000000000645
|
[16]
|
Ménétrier-Caux, C., Ray-Coquard, I., Blay, J.Y. and Caux, C. (2019) Lymphopenia in Cancer Patients and Its Effects on Response to Immunotherapy: An Opportunity for Combi-nation with Cytokines? Journal for ImmunoTherapy of Cancer, 7, 85. https://doi.org/10.1186/s40425-019-0549-5
|
[17]
|
傅郗雨菁, 杨顺娥. 中性粒细胞与淋巴细胞比值对弥漫性大B细胞淋巴瘤预后判断的意义[J]. 现代肿瘤医学, 2022, 30(22): 4162-4166.
|
[18]
|
Mu, S.D., Ai, L.S., Fan, F.J., Qin, Y., Sun, C.Y. and Hu, Y. (2018) Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Diffuse Large B Cell Lympho-ma Patients: An Updated Dose-Response Meta-Analysis. Cancer Cell International, 18, Article No. 119. https://doi.org/10.1186/s12935-018-0609-9
|
[19]
|
Wang, J., Zhou, X., Liu, Y., Li, Z. and Li, X. (2017) Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Diffuse Large B-Cell Lymphoma: A Meta-Analysis. PLOS ONE, 12, e0176008.
https://doi.org/10.1371/journal.pone.0176008
|
[20]
|
Feng, J.H., Wang, Z.J., Guo, X.P., Chen, Y.Y., Cheng, Y.P. and Tang, Y.M. (2012) Prognostic Significance of Absolute Lymphocyte Count at Diagnosis of Diffuse Large B-Cell Lymphoma: A Meta-Analysis. International Journal of Hematology, 95, 143-148. https://doi.org/10.1007/s12185-011-0993-6
|
[21]
|
Annibali, O., Hohaus, S., Marchesi, F., Cantonetti, M., Di Rocco, A., Tomarchio, V., Di Napoli, A., Pelliccia, S., Battistini, R., Anticoli Borza, P., Abruzzese, E., Cenfra, N., Andriani, A., Tesei, C., Alma, E., Palombi, F., Pupo, L., Petrucci, L., Becilli, M., Maiolo, E., Bellesi, S., Cuccaro, A., D’Alò, F. and Cox Maria, C. (2019) The Neutrophil/Lymphocyte Ratio ≥ 3.5 Is a Prognostic Marker in Diffuse Large B-Cell Lym-phoma: A Retrospective Analysis from the Database of the Italian Regional Network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI). Leukemia & Lymphoma, 60, 3386-3394. https://doi.org/10.1080/10428194.2019.1633628
|
[22]
|
Antonangeli, F., Natalini, A., Garassino, M.C., et al. (2020) Regulation of PD-L1 Expression by NF-κB in Cancer. Frontiers in Immunology, 11, Article 584626. https://doi.org/10.3389/fimmu.2020.584626
|
[23]
|
Lesokhin, A.M., Ansell, S.M., Armand, P., Scott, E.C., Halwani, A., Gutierrez, M., et al. (2016) Nivolumab in Patients with Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. Journal of Clinical Oncology, 34, 2698-2704. https://doi.org/10.1200/JCO.2015.65.9789
|
[24]
|
Hernandez-Ilizaliturri, F.J., Deeb, G., Zinzani, P.L., Pileri, S.A., Malik, F., Macon, W.R., et al. (2011) Higher Response to Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Nongerminal Center B-Cell-Like than in Germinal Center B-Cell-Like Phenotype. Cancer, 117, 5058-5066. https://doi.org/10.1002/cncr.26135
|
[25]
|
Feldman, T., Mato, A.R., Chow, K.F., Protomastro, E.A., Yannotti, K.M., Bhattacharyya, P., et al. (2014) Addition of Lenalidomide to Rituximab, Ifosfamide, Carboplatin, Etoposide (RICER) in First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma. British Journal of Haematology, 166, 77-83. https://doi.org/10.1111/bjh.12846
|
[26]
|
Martin, A., Redondo, A.M., Dlouhy, I., Salar, A., Gonzalez-Barca, E., Canales, M., et al. (2016) Lenalidomide in Combination with R‑ESHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 1b Study from GELTAMO Group. British Journal of Haematology, 173, 245-252. https://doi.org/10.1111/bjh.13945
|
[27]
|
Ghesquieres, H., Chevrier, M., Laadhari, M., Chinot, O., Choquet, S., Molucon-Chabrot, C., et al. (2019) Lenalidomide in Combination with Intravenous Rituximab (REVRI) in Re-lapsed/Refractory Primary CNS Lymphoma or Primary Intraocular Lymphoma: A Multicenter Prospective “Proof of Concept” Phase II Study of the French Oculo‑Cerebral Lymphoma (LOC) Network and the Lymphoma Study Associa-tion (LYSA) Dagger. Annals of Oncology, 30, 621-628. https://doi.org/10.1093/annonc/mdz032
|
[28]
|
Rubenstein, J.L., Geng, H., Fraser, E.J., Formaker, P., Chen, L., Sharma, J., et al. (2018) Phase 1 Investigation of Lenalido-mide/Rituximab plus Outcomes of Lenalidomide Maintenance in Relapsed CNS Lymphoma. Blood Advances, 2, 1595-1607. https://doi.org/10.1182/bloodadvances.2017014845
|
[29]
|
Niiro, H. and Clark, E.A. (2002) Regulation of B-Cell Fate by Antigen-Receptor Signals. Nature Reviews Immunology, 2, 945-956. https://doi.org/10.1038/nri955
|
[30]
|
Merolle, M.I., Ahmed, M., Nomie, K., et al. (2018) The B Cell Receptor Sig-naling Pathway in Mantle Cell Lymphoma. Oncotarget, 9, 25332-25341. https://doi.org/10.18632/oncotarget.25011
|
[31]
|
Shadman, M., Pasquini, M., Ahn, K.W., Chen, Y., Turtle, C.J., Hematti, P., Cohen, J.B., Khimani, F., Ganguly, S., Merryman, R.W., Yared, J.A., Locke, F.L., Ahmed, N., Munshi, P.N., Beitinjaneh, A., Reagan, P.M., Herrera, A.F., Sauter, C.S., Kharfan-Dabaja, M.A. and Hamadani, M. (2022) Au-tologous Transplant vs Chimeric Antigen Receptor T-Cell Therapy for Relapsed DLBCL in Partial Remission. Blood, 139, 1330-1339.
https://doi.org/10.1182/blood.2021013289
|
[32]
|
黄玉洁, 黄鑫, 郭宝平, 等. 基于肿瘤免疫微环境的弥漫大B细胞淋巴瘤预后分析[J]. 肿瘤预防与治疗, 2021, 34(2): 108-116.
|
[33]
|
Villanueva, M.T. (2020) Macrophages Get a CAR. Nature Reviews Cancer, 20, 300.
https://doi.org/10.1038/s41568-020-0259-9
|
[34]
|
Pan, K., Farrukh, H., Chittepu, V.C.S.R., et al. (2022) CAR Race to Cancer Immunotherapy: From CAR-T, CAR NK to CAR Macrophage Therapy. Journal of Experimental and Clinical Cancer Research, 41, Article No. 119.
https://doi.org/10.1186/s13046-022-02327-z
|
[35]
|
Schmitt, A., Xu, W., Bucher, P., Grimm, M., Konantz, M., Horn, H., Zapukhlyak, M., Berning, P., Brändle, M., Jarboui, M.A., Schönfeld, C., Boldt, K., Rosenwald, A., Ott, G., Grau, M., Klener, P., Vockova, P., Lengerke, C., Lenz, G., Schulze-Osthoff, K. and Hailfinger, S. (2021) Dimethyl Fumarate Induces Ferroptosis and Impairs NF-κB/STAT3 Signaling in DLBCL. Blood, 138, 871-884. https://doi.org/10.1182/blood.2020009404
|